Navigation Links
GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
Date:9/10/2009

NEW YORK, Sept. 10 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

Aaron Whiteman, CEO for GENova says, "Following a rigorous evaluation phase, we have selected three potential blockbuster drug target patents for acquisition, and we look forward to integrating them into our IP portfolio." The acquisition targets still subject to due diligence and contract would include both preclinical and clinical drugs that show promising potential in the major markets of anti-cancer and anti-infective drugs.

GENova will announce details of these new biological products in the coming weeks.

GENova's Current IP Portfolio

The three new patents would join GENova's current proprietary IP products --tetanolic acid (for breast cancer) and prostaganin (for prostate cancer)-- in the company's growing IP portfolio.

Known as an alpha hydroxyoleic acid, tetanolic acid is a form of a lipid that has the demonstrated ability to affect the growth and proliferation of cells. Seeing that cancer is characterised as a normal proliferation of cells, these lipids can potentially prevent cancer spread. Preliminary tests in mice have shown that the protein can prevent the growth and spread of cancer in mice. GENova's Tetanolic acid is therefore a prime candidate for development of an anti-cancer medicament in humans. The breast cancer therapeutics market is expected to grow from its current level of US$5.9 billion (EUR5 million) to $11.5 billion by 2011, with a compound annual growth rate (CAGR) of 9.8 per cent (Frost Sullivan).

GENova's proprietary peptide for prostate cancer, Prostaganin, de
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. GENova files patent for new breast cancer treatment
2. GENova appoints Director of Asian business development
3. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. Genova files patent for new prostate cancer treatment
6. GENova names Dr. John Savin as Vice President
7. GENova names Aaron Whiteman as CEO
8. Kapstone Medical Acquires Exclusive License to New Orthopedic Technology
9. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A.
10. Abbott to Acquire Visiogen, Expanding Vision Care Portfolio
11. Danaher to Acquire Life Sciences Instrumentation Businesses From MDS Inc. and Life Technologies Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013, PHILADELPHIA ─ The negative effects of poorly ... performance in urban schoolchildren has been confirmed in ... been recognized that missed sleep and school absences ... our study is the first to explore the ... in real time, prospectively, using both objective ...
(Date:5/21/2013)... physical activity appears to be an independent predictor ... pulmonary disease (COPD) will end up being hospitalized, ... in Connecticut. The study also corroborates an earlier ... an increased incidence of hospitalizations among patients with ... be presented at the ATS 2013 International Conference. ...
(Date:5/21/2013)... 2013, PHILADELPHIA ─ A novel approach to obstructing ... of asthma has shown promise in a Phase ... , Their research will be presented at the ... simultaneously online in the New England Journal ... trial tested the efficacy and safety of the ...
(Date:5/21/2013)... PHILADELPHIA─Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a ... breakdown and protects the lung,s elasticity, is effective ... with Alpha-1 antitrypsin deficiency (AATD), a life-threatening genetic ... the 2013 American Thoracic Society International Conference. , ... the loss of lung tissue as measured by ...
(Date:5/21/2013)... After the success of its inaugural 1,000 lb. ... Body Boot Camp Goderich will be hosting its 2nd Annual ... Goderich fitness center located at 199 Anglesea Street Goderich, ... goal is to inspire and motivate local community residents to ... The fee to participate is discounted to $40 for the ...
Breaking Medicine News(10 mins):Health News:Asthma symptoms impair sleep quality and school performance in children 2Health News:Exercise levels may predict hospitalizations in COPD population 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 2Health News:Monoclonal antibody appears effective and safe in asthma Phase IIa trial 3Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 3Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 2Health News:Goderich Fitness Center Promotes 2nd Annual 1,000 lb. Meltdown Challenge to Fight Obesity With All Proceeds Raised Going to Local Charity 3
... of Public Health reported that most of the flu shot ... to the department, 94% of the state's total order has ... 24. Over 1.7 million vaccines will be stocked that includes ... Centers for Disease Control and Prevention revealed that this flu ...
... The World Health Organization (WHO), on Friday, had initiated the ... prevent infections associated //with Health care practices. WHO said that ... costs but also will save lives. ,It is ... by the infections caused by the hospitals, which are mainly ...
... are more likely to develop certain types of cancer ... // ,Grace LeMasters and colleagues at the ... fire fighters from 32 previously published scientific studies to ... of their profession, reported science portal EurekAlert. ...
... recent study revealed that consuming just two cups of green ... Texas in collaboration with their counterparts in the UK carried ... online edition of the Journal of Allergy and Clinical Immunology. ... (EGCG) present in green tea has the ability to block ...
... disease are alarming. According to a news release by McGill ... Canada and 8,500 deaths from the disease are expected every ... deaths, as reported by the Centers for Disease Control and ... and 16,000 deaths. ,However, here is some good ...
... the eyes can diagnose cerebral malaria in children, according ... complication where the Plasmodium falciparum parasite infects capillaries that ... to detect as patients can be unconscious and have ... ratio in cerebral malaria is 25-50 percent, reported science ...
Cached Medicine News:Health News:The Anti-HIV Properties Of Green Tea Uncovered 2
(Date:5/20/2013)... GLENWOOD, Ill. , May 20, 2013 ... leader in personal and environmental radiation measurement and monitoring, ... accessories, announced today that its Board of Directors declared, ... quarterly cash dividend of $0.55 per share for the ... paid on July 3, 2013, to shareholders of record ...
(Date:5/20/2013)... , May 20, 2013   National Community ... Hoey , RPh, MBA issued the following statement ... Associates regarding Medicare Part D "preferred pharmacy" drug ... offering patients the plan,s lowest advertised co-payments: ... Medicare and MedPAC , 16 ...
(Date:5/20/2013)...  TRACE International today released its Global Enforcement ... against individuals and government or business entities for bribery ... 2012 is the third in an annual series ... "Although the number of outbound enforcement actions fell ... priority," said Alexandra Wrage , TRACE ...
Breaking Medicine Technology:Landauer, Inc. Declares Regular Cash Dividend 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 2Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 3Poll: Over One Million Seniors Have Problems with Medicare 'Preferred Pharmacy' Drug Plans 4TRACE Releases 2012 Global Enforcement Report 2TRACE Releases 2012 Global Enforcement Report 3
... Elsevier, the world-leading publisher of ... announced today that its 2012 eBook Frontlist collections ... Elsevier,s online platform for scientific content. This release ... depth of the eBook collection on SciVerse ScienceDirect. ...
... 2011 Baxa Corporation , a leading provider ... has released a software upgrade for its ExactaMix® ... 14 updates that provide Directors of Pharmacy with enhanced ... worldwide use ExactaMix 2400 (EM2400) and ExactaMix 1200 (EM1200) ...
Cached Medicine Technology:Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase 2Elsevier Announces New 2012 Frontlist eBooks Collection on SciVerse ScienceDirect Available for Advance Purchase 3Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 2Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 3Baxa Corporation Bolsters Patient Safety With ExactaMix® Compounder Software Upgrade 4
... Helmer PC1200 Platelet Incubators ... your laboratory counter top. These ... institution to have the security ... environment without taking up a ...
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... rotators and agitators for continual ... set at 22C (71F) or ... (59F to 104F). Uniformity is ... bottom. Recorder is standard on ...
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Medicine Products: